FDA approves generic versions of Novartis epilepsy drug

Share this article:

The FDA has approved the first generic versions of Novartis' epilepsy treatment Trileptal (oxcarbazepine).

Roxane Laboratories, Sun Pharmaceuticals and Glenmark Pharmaceuticals won approval to sell versions of oxcarbazepine in three strengths – 150 mgs 300 mgs, and 600 mgs.

US sales of Trileptal were $549 million in 2006.

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.